Single User License
INR 135120
Site License
INR 270240
Corporate User License
INR 405360

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Peripheral Artery Occlusive Disease (PAOD)-Pipeline Review, H1 2015

Peripheral Artery Occlusive Disease (PAOD)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Peripheral Artery Occlusive Disease (PAOD)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Peripheral Artery Occlusive Disease (PAOD)-Pipeline Review, H1 2015', provides an overview of the Peripheral Artery Occlusive Disease (PAOD)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peripheral Artery Occlusive Disease (PAOD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Artery Occlusive Disease (PAOD) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Peripheral Artery Occlusive Disease (PAOD)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Peripheral Artery Occlusive Disease (PAOD) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Peripheral Artery Occlusive Disease (PAOD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Peripheral Artery Occlusive Disease (PAOD) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Peripheral Artery Occlusive Disease (PAOD)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Peripheral Artery Occlusive Disease (PAOD) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Peripheral Artery Occlusive Disease (PAOD) Overview 11

Therapeutics Development 12

Pipeline Products for Peripheral Artery Occlusive Disease (PAOD)-Overview 12

Pipeline Products for Peripheral Artery Occlusive Disease (PAOD)-Comparative Analysis 13

Peripheral Artery Occlusive Disease (PAOD)-Therapeutics under Development by Companies 14

Peripheral Artery Occlusive Disease (PAOD)-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Unknown Stage Products 21

Peripheral Artery Occlusive Disease (PAOD)-Products under Development by Companies 22

Peripheral Artery Occlusive Disease (PAOD)-Companies Involved in Therapeutics Development 26

Annexin Pharmaceuticals AB 26

Apceth GmbH & Co. KG 27

AstraZeneca PLC 28

Athersys, Inc. 29

Bayer AG 30

Betagenon AB 31

Cardiolynx AG 32

CardioVascular BioTherapeutics, Inc. 33

Celgene Corporation 34

Cytokinetics, Inc. 35

Diffusion Pharmaceuticals LLC 36

DNAVEC Corporation 37

Genovate Biotechnology Co., LTD. 38

Grifols, S.A. 39

Human Stem Cells Institute 40

Kowa Company, Ltd. 41

Lacer, S.A. 42

Ligand Pharmaceuticals, Inc. 43

LTT Bio-Pharma Co., Ltd. 44

miRagen Therapeutics, Inc. 45

Multi Gene Vascular Systems Ltd 46

Nuo Therapeutics, Inc. 47

Pluristem Therapeutics Inc. 48

Proteon Therapeutics, Inc. 49

Recardio GmbH 50

RegenoCELL Therapeutics, Inc. 51

Rigel Pharmaceuticals, Inc. 52

Sagene Pharmaceuticals, Inc. 53

Stemedica Cell Technologies, Inc. 54

Taisho Toyama Pharmaceutical Co., Ltd. 55

Theravasc, Inc. 56

vasopharm GmbH 57

ViroMed Co., Ltd. 58

Peripheral Artery Occlusive Disease (PAOD)-Therapeutics Assessment 59

Assessment by Monotherapy Products 59

Assessment by Combination Products 60

Assessment by Target 61

Assessment by Mechanism of Action 63

Assessment by Route of Administration 65

Assessment by Molecule Type 67

Drug Profiles 69

(cilostazol + organic nitrate) ER-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

AEM-28-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

ALD-301-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

Alecmestencel-T-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

alprostadil-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

Annexin A-5-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

AP-01-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

cilostazol CR-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

clopidogrel bisulfate-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

CVBT-141C-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

DVC1-0101-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

ELS-140-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Human Plasmin-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

K-134-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

LA-419-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

LT-0101-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

Mesenchymal Stem Cells-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

MGN-6114-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

MultiGeneAngio-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

MultiGeneGraft-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

MultiStem-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

O-304-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

PDA-002-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

R-118-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

REC-03-Drug Profile 101

Product Description 101

Mechanism of Action 101

R&D Progress 101

rivaroxaban-Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

selegiline + Antiplatelet Drugs-Drug Profile 107

Product Description 107

Mechanism of Action 107

R&D Progress 107

sodium nitrite-Drug Profile 108

Product Description 108

Mechanism of Action 108

R&D Progress 108

Stem Cell Therapy for Cardiovascular Diseases-Drug Profile 110

Product Description 110

Mechanism of Action 110

R&D Progress 110

Stem Cell Therapy for Cardiovascular Diseases-Drug Profile 112

Product Description 112

Mechanism of Action 112

R&D Progress 112

SYN-20112312RU-Drug Profile 113

Product Description 113

Mechanism of Action 113

R&D Progress 113

ticagrelor-Drug Profile 114

Product Description 114

Mechanism of Action 114

R&D Progress 114

tirasemtiv-Drug Profile 117

Product Description 117

Mechanism of Action 117

R&D Progress 117

transcrocetinate sodium-Drug Profile 123

Product Description 123

Mechanism of Action 123

R&D Progress 123

TXA-127-Drug Profile 124

Product Description 124

Mechanism of Action 124

R&D Progress 124

VAS-2870-Drug Profile 126

Product Description 126

Mechanism of Action 126

R&D Progress 126

VM-202-Drug Profile 127

Product Description 127

Mechanism of Action 127

R&D Progress 127

vonapanitase-Drug Profile 129

Product Description 129

Mechanism of Action 129

R&D Progress 129

Peripheral Artery Occlusive Disease (PAOD)-Recent Pipeline Updates 130

Peripheral Artery Occlusive Disease (PAOD)-Dormant Projects 166

Peripheral Artery Occlusive Disease (PAOD)-Discontinued Products 171

Peripheral Artery Occlusive Disease (PAOD)-Product Development Milestones 173

Featured News & Press Releases 173

Feb 02, 2015: The Small molecule AMPK activator O304 acts as an oral PCSK9 inhibitor 173

Jan 08, 2015: Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease 173

Sep 29, 2014: Annexin Pharmaceuticals Announces Patent 174

Sep 02, 2014: Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals 174

Jul 09, 2014: Development Of Russian Innovative Drug For Peripheral Arterial Disease Is Supported By The Council Of Maryland Biotech Companies (USA) 175

Mar 17, 2014: AstraZeneca Announces Progress on Global PARTHENON Clinical Trial Program with BRILINTA in High-Risk Cardiovascular Disease Patient Populations in Advance of American College of Cardiology Scientific Session 176

Mar 06, 2014: Rigel Announces Publication of R118 AMPK Activator Research 178

Nov 13, 2013: Pluristem Receives Regulatory Approval to Extend Its Phase II Study of PLX-PAD Cells in the Treatment of Intermittent Claudication to South Korea 179

Oct 02, 2013: Pluristem Receives Israeli Ministry of Health Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Israel 180

Sep 16, 2013: FDA Lifts Clinical Hold of Pluristem's Phase II Intermittent Claudication Study 180

Appendix 181

Methodology 181

Coverage 181

Secondary Research 181

Primary Research 181

Expert Panel Validation 181

Contact Us 181

Disclaimer 182

List of Tables

Number of Products under Development for Peripheral Artery Occlusive Disease (PAOD), H1 2015 12

Number of Products under Development for Peripheral Artery Occlusive Disease (PAOD)-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 15

Number of Products under Development by Companies, H1 2015 (Contd..1) 16

Number of Products under Development by Companies, H1 2015 (Contd..2) 17

Comparative Analysis by Late Stage Development, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Development, H1 2015 20

Comparative Analysis by Unknown Stage Development, H1 2015 21

Products under Development by Companies, H1 2015 22

Products under Development by Companies, H1 2015 (Contd..1) 23

Products under Development by Companies, H1 2015 (Contd..2) 24

Products under Development by Companies, H1 2015 (Contd..3) 25

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Annexin Pharmaceuticals AB, H1 2015 26

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Apceth GmbH & Co. KG, H1 2015 27

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by AstraZeneca PLC, H1 2015 28

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Athersys, Inc., H1 2015 29

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Bayer AG, H1 2015 30

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Betagenon AB, H1 2015 31

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Cardiolynx AG, H1 2015 32

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by CardioVascular BioTherapeutics, Inc., H1 2015 33

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Celgene Corporation, H1 2015 34

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Cytokinetics, Inc., H1 2015 35

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Diffusion Pharmaceuticals LLC, H1 2015 36

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by DNAVEC Corporation, H1 2015 37

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Genovate Biotechnology Co., LTD., H1 2015 38

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Grifols, S.A., H1 2015 39

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Human Stem Cells Institute, H1 2015 40

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Kowa Company, Ltd., H1 2015 41

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Lacer, S.A., H1 2015 42

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 43

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015 44

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by miRagen Therapeutics, Inc., H1 2015 45

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Multi Gene Vascular Systems Ltd, H1 2015 46

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Nuo Therapeutics, Inc., H1 2015 47

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Pluristem Therapeutics Inc., H1 2015 48

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Proteon Therapeutics, Inc., H1 2015 49

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Recardio GmbH, H1 2015 50

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by RegenoCELL Therapeutics, Inc., H1 2015 51

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Rigel Pharmaceuticals, Inc., H1 2015 52

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Sagene Pharmaceuticals, Inc., H1 2015 53

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Stemedica Cell Technologies, Inc., H1 2015 54

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Taisho Toyama Pharmaceutical Co., Ltd., H1 2015 55

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by Theravasc, Inc., H1 2015 56

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by vasopharm GmbH, H1 2015 57

Peripheral Artery Occlusive Disease (PAOD)-Pipeline by ViroMed Co., Ltd., H1 2015 58

Assessment by Monotherapy Products, H1 2015 59

Assessment by Combination Products, H1 2015 60

Number of Products by Stage and Target, H1 2015 62

Number of Products by Stage and Mechanism of Action, H1 2015 64

Number of Products by Stage and Route of Administration, H1 2015 66

Number of Products by Stage and Molecule Type, H1 2015 68

Peripheral Artery Occlusive Disease (PAOD) Therapeutics-Recent Pipeline Updates, H1 2015 130

Peripheral Artery Occlusive Disease (PAOD)-Dormant Projects, H1 2015 166

Peripheral Artery Occlusive Disease (PAOD)-Dormant Projects (Contd..1), H1 2015 167

Peripheral Artery Occlusive Disease (PAOD)-Dormant Projects (Contd..2), H1 2015 168

Peripheral Artery Occlusive Disease (PAOD)-Dormant Projects (Contd..3), H1 2015 169

Peripheral Artery Occlusive Disease (PAOD)-Dormant Projects (Contd..4), H1 2015 170

Peripheral Artery Occlusive Disease (PAOD)-Discontinued Products, H1 2015 171

Peripheral Artery Occlusive Disease (PAOD)-Discontinued Products (Contd..1), H1 2015 172

List of Figures

Number of Products under Development for Peripheral Artery Occlusive Disease (PAOD), H1 2015 12

Number of Products under Development for Peripheral Artery Occlusive Disease (PAOD)-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Products, H1 2015 20

Assessment by Monotherapy Products, H1 2015 59

Number of Products by Top 10 Targets, H1 2015 61

Number of Products by Stage and Top 10 Targets, H1 2015 61

Number of Products by Top 10 Mechanism of Actions, H1 2015 63

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 63

Number of Products by Top 10 Routes of Administration, H1 2015 65

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 66

Number of Products by Top 10 Molecule Types, H1 2015 67

Number of Products by Stage and Top 10 Molecule Types, H1 2015 68

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Annexin Pharmaceuticals AB

Apceth GmbH & Co. KG

AstraZeneca PLC

Athersys, Inc.

Bayer AG

Betagenon AB

Cardiolynx AG

CardioVascular BioTherapeutics, Inc.

Celgene Corporation

Cytokinetics, Inc.

Diffusion Pharmaceuticals LLC

DNAVEC Corporation

Genovate Biotechnology Co., LTD.

Grifols, S.A.

Human Stem Cells Institute

Kowa Company, Ltd.

Lacer, S.A.

Ligand Pharmaceuticals, Inc.

LTT Bio-Pharma Co., Ltd.

miRagen Therapeutics, Inc.

Multi Gene Vascular Systems Ltd

Nuo Therapeutics, Inc.

Pluristem Therapeutics Inc.

Proteon Therapeutics, Inc.

Recardio GmbH

RegenoCELL Therapeutics, Inc.

Rigel Pharmaceuticals, Inc.

Sagene Pharmaceuticals, Inc.

Stemedica Cell Technologies, Inc.

Taisho Toyama Pharmaceutical Co., Ltd.

Theravasc, Inc.

vasopharm GmbH

ViroMed Co., Ltd.

Peripheral Artery Occlusive Disease (PAOD) Therapeutic Products under Development, Key Players in Peripheral Artery Occlusive Disease (PAOD) Therapeutics, Peripheral Artery Occlusive Disease (PAOD) Pipeline Overview, Peripheral Artery Occlusive Disease (PAOD) Pipeline, Peripheral Artery Occlusive Disease (PAOD) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com